Contact: Sophie Mohin, 914-740-2254, Smohin@liebertpub.com
Groundbreaking New Model for Predicting Vaccine Efficacy and Safety
New Rochelle, NY, May 14, 2012—Vaccine testing and development is an extremely lengthy and complex process that costs billions of dollars every year. In an effort to dramatically improve the speed and success of vaccine research and development, researchers have created an innovative biomimetic model of the human immune system known as the MIMIC® system. An article in the inaugural issue of Disruptive Science and Technology, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers describes this artificial human immune system which can facilitate faster, more effective vaccine development. The article “In vitro Biomimetic Model of the Human Immune System for Predictive Vaccine Assessments” is available on the Disruptive Science and Technology website.
“Our goal is to increase the likelihood of success within the clinic– to make better drugs and vaccines and get them into the marketplace and to the patients faster,” says William Warren, PhD, Head of the VaxDesign Campus of Sanofi Pasteur, the vaccines division of Sanofi. “This in vitro human immune system enables us to measure vaccine efficacy earlier and more predictably.”
The MIMIC® platform represents a truly disruptive technology for the study of vaccines and other biologics with immunomodulatory potential, as it provides a novel in vitro model for evaluating human immune responses against candidate drugs, adjuvants, and vaccines. It has shown game-changing advantages over conventional approaches to safety and efficacy testing.
About the Journal
Disruptive Science and Technology, a breakthrough, highly innovative, peer-reviewed journal spearheaded by Editor-in-Chief Alan J. Russell, PhD, Highmark Distinguished Professor, Carnegie Mellon University, cultivates, harnesses, and explores how existing paradigms can be changed to improve human health, well-being, and productivity. The Journal provides a multimedia platform and forum for ideas and opportunities, promotes breakthrough science and engineering, facilitates the innovator-market relationship, and accelerates the transition from bench to society. Bold, transparent, and resistant to limitations driven by protection of the science and engineering status quo, Disruptive Science and Technology provides the first destination for those seeking to publish game-changing results that have the capacity to alter the way we live. For complete journal details, please visit the Disruptive Science and Technology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Human Gene Therapy and HGT Methods, and Rejuvenation Research. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc. website.